- 5F-PB-22
- AM-2201 carboxylate analogue quinolinyl derivative
- 5F-QUPIC
- QU-5F-PIC
Mogler, L; Franz, F; Rentsch, D; Angerer, V; Weinfurtner, G; Longworth, M; Banister, SD; Kassiou, M; Moosmann, B; Auwärter, V. Detection of the recently emerged synthetic cannabinoid 5F–MDMB-PICA in ‘legal high’ products and human urine samples Drug Test. Anal., 1 Jan 2018, 10 (1), 196-205. 1.0 MB. https://doi.org/10.1002/dta.2201 #5F-PB-22 MS
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Smolianitski-Fabian, E; Cohen, E; Dronova, M; Voloshenko-Rossin, A; Lev, O. Discrimination between closely related synthetic cannabinoids by GC-Cold-EI-MS Drug Test. Anal., 1 Mar 2018, 10 (3), 474-487. 1.3 MB. https://doi.org/10.1002/dta.2247 #5F-PB-22 MS
Dunne, SJ; Rosengren-Holmberg, JP. Quantification of synthetic cannabinoids in herbal smoking blends using NMR Drug Test. Anal., 1 May 2017, 9 (5), 734-743. 988 kB. https://doi.org/10.1002/dta.2032
Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #5 fluoro PB 22 LC,MS
Zawilska, JB; Andrzejczak, D. Next generation of novel psychoactive substances on the horizon – A complex problem to face Drug Alcohol Depend., 1 Jan 2015, 157, 1-17. 3.0 MB. https://doi.org/10.1016/j.drugalcdep.2015.09.030
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #6. 5F-PB-22
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #18
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #39
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #5F-PB-22
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #5F-PB-22
Okamoto, K; Akimoto, S; Ando, T; Ikeda, Y; Kurashima, N. Differentiation of regioisomeric analogs of controlled substances using GC-IR JCCL, 1 Oct 2016, (56), 49–70. 4.5 MB. #5F-QUPIC Japanese, English abstract GC,MS,IR
Wouters, E; Walraed, J; Robertson, MJ; Meyrath, M; Szpakowska, M; Chevigné, A; Skiniotis, G; Stove, C. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds ACS Pharmacol. Transl. Sci., 10 Apr 2020, 3 (2), 285–295. 2.0 MB. https://doi.org/10.1021/acsptsci.9b00069 #10
Kikura-Hanajiri, R. New designer drugs in japan In Neuropathology of Drug Addictions and Substance Misuse; Preedy, VR, Ed., Academic Press, 1 Jan 2016; pp 1055–1065. 682 kB. https://doi.org/10.1016/B978-0-12-800212-4.00097-2 #5-Fluoro PB-22
Kondrasenko, AA; Goncharov, EV; Dugaev, KP; Rubaylo, AI. CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate Forensic Sci. Int., 1 Dec 2015, 257, 209–213. 319 kB. https://doi.org/10.1016/j.forsciint.2015.08.023 #5F-PB-22 MS,NMR,IR
Uchiyama, N; Matsuda, S; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products Forensic Toxicol., 1 Jan 2014, 32 (1), 9–18. 678 kB. https://doi.org/10.1007/s11419-013-0194-5 #4 MS,NMR,UV
Andrews, R; Jorge, R; Christie, R; Gallegos, A. From JWH‐018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day Drug Test. Anal., 1 Apr 2023, 15 (4), 378–387. 1.2 MB. https://doi.org/10.1002/dta.3422 #5F-PB-22